LILRB4 and cancer: Additional modalities have also been developed and tested for targeting LILRB4 in cancer therapy, including antibody drug conjugates for direct cytotoxicity of LILRB4 expressing tumor associated myeloid cells, and LILRB4 CAR-T cells for targeting LILRB4 expressing leukemic cells (117, 118).